<DOC>
	<DOCNO>NCT00264628</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability efficacy oral GW679769 120 mg dose compare placebo patient ACR ( American College Rheumatology ) -defined fibromyalgia , co-morbid depression .</brief_summary>
	<brief_title>GW679769 In Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Casopitant</mesh_term>
	<criteria>Inclusion criterion : Diagnosis fibromyalgia ( ACR criterion ) . Nonsevere depression ( HAMD score &gt; 14 &lt; 24 ) . Women must commit consistent use acceptable method birth control . Exclusion criterion : Severe depression ( HAMD score &gt; 24 ) . Unable discontinue medication pain depression . Laboratory ECG value screen outside sponsor define range . Positive stool occult blood test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>NK1-antagonist</keyword>
	<keyword>Depression</keyword>
	<keyword>Fibromyalgia</keyword>
	<keyword>GW679769</keyword>
	<keyword>Outpatient</keyword>
</DOC>